AstraZeneca Confirms Interest In 'Next-Generation Imbruvica' Play
This article was originally published in Scrip
AstraZeneca has published a short statement confirming that it is "exploring potential strategic options" with Acerta Pharma BV. The move is in response to recent speculation that AstraZeneca is pursuing the Dutch blood cancer company and has offered around $5bn.
Register for our free email digests: